Once-daily fleroxacin versus twice-daily ciprofloxacin in the treatment of complicated urinary tract infections

Journal of Urology

Volumn 158, Issue 4, 1997, Pages 1494-1499

  Frankenschmidt, Alexander ^a,e   Naber, Kurt G ^b,e   Bischoff, Werner ^c,e   Kullmann, Karlheinz ^d,e   Basting, R F ^e   Ecke, M ^e   Eckmeyer, J ^e   Frohmuller H ^e   Hofmockel, G ^e   Hahn, E ^e   Anger, U ^e   Hautmann, R ^e   Hofstetter, A ^e   Brunschweiger, S ^e   Helmbrecht, J ^e   Junginger, J ^e   Leusmann, D B ^e   Muller G W ^e   Muller Mattheis V ^e   Riedmiller, H ^e   Weingartner K ^e   Saschowa, P ^e   Savov, O ^e   Schabel, J ^e   Richter, M ^e   Schalkhauser K ^e   Steinhauer, H B ^e   Tauber, R ^e   Tauchnitz, C ^e   Tunn, U W ^e   Bauer, L ^e   Walz, P H ^e   Westenfelder, M ^e   Wienhower R ^e   Wehrmann, E ^e   Wirth, M ^e   more..

^a UNIVERSITY OF FREIBURG   (Germany)

^b Urologische Klinik   (Germany)

^c District Hospital   (Germany)

^d ROCHE INNOVATION CENTER MUNICH   (Germany)

^e NONE

Author keywords

Bacteriology; Ciprofloxacin; Quinolinones; Urinary tract infections

Indexed keywords

CIPROFLOXACIN; FLEROXACIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; URINARY TRACT INFECTION;

EID: 0030852385     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64252-6     Document Type: Article

References (23)

1. Bailey, R. R.: Review of published studies on single dose therapy of urinary tract infections. Infection, suppl. 2, 18: S53, 1990.
2. Stamm, W. E. and Hooton, T. M.: Management of urinary tract infections in adults. New Engl. J. Med., 329: 1328, 1993.
3. Hooper, D. C. and Wolfson, J. S.: Fluoroquinolone antimicrobial agents. New Engl. J. Med., 324: 384, 1991.
4. Naber, K. G.: Use of quinolones in urinary tract infections and prostatitis. Rev. Infect. Dis., suppl., 11: S1321, 1989.
5. Nightingale, C. H.: Implication of fleroxacin's pharmacokinetic profile. Int. J. Antimicrob. Agents, suppl. 2, 4: S7, 1994.
6. Iravani, A.: Multicenter study of single-dose and multiple-dose fleroxacin versus ciprofloxacin in the treatment of uncomplicated urinary tract infections. Amer. J. Med., suppl. 3A, 94: S89, 1993.
7. Kosmidis, J., Gargalianos, P., Adamis, G., Petropoulou, D. and Makris, D.: Fleroxacin in single dose oral therapy of uncomplicated lower urinary tract infections. J. Antimicrob. Chemother., suppl. D, 22: S219, 1988.
8. Naber, K. G.: Uncomplicated urinary tract infections - is single-dose therapy effective? Int. J. Antimicrob. Agents, suppl. 2, 4: S39, 1994.
9. Pummer, K.: Fleroxacin versus norfloxacin in the treatment of urinary tract infections: a multicenter, double-blind, prospective randomized comparative study. Amer. J. Med., suppl. 3A, 94: 108S, 1993.
10. Pittman, W., Moon, J. O., Hamrick, L. C., Jr., Cox, C. E., Clark, J., Childs, S., Pizzuti, D., Fredericks, J. and St. Clair, P.: Randomized double-blind trial of high- and low-dose fleroxacin versus norfloxacin for complicated urinary tract infection. Amer. J. Med., suppl. 3A, 94: 101S, 1993.
11. Naber, K. G. and Sigl, G.: Fleroxacin versus ofloxacin in patients with complicated urinary tract infections: a controlled clinical study. Amer. J. Med., suppl. 3A, 94: 114S, 1993.
12. Childs, S. J.: Fleroxacin versus norfloxacin for oral treatment of serious urinary tract infections. Amer. J. Med., suppl. 3A, 94: 105S, 1993.
13. Cox, C. E.: Comparison of intravenous fleroxacin with ceftazidime for treatment of complicated urinary tract infections. Amer. J. Med., suppl. 3A, 94: 118S, 1993.
14. Taufer, M., Pummer, K. and Primus, G.: Fleroxacin versus norfloxacin in the therapy of complicated urinary tract infection: a randomized, multidose, double-blind study. Rev. Infect. Dis., suppl. 5, 11: S1353, 1989.
15. Cullmann, W., Geddes, A. M., Weidekamm, E., Urwyler, H. and Braunsteiner, A.: Fleroxacin: a review of its chemistry, microbiology, toxocology, pharmacokinetics, clinical efficay and safety. Int. J. Antimicrob. Agents, 2: 203, 1993.
16. Jones, R. N., Erwin, M. E., Hager, H. L. and Hohl, P. E.: Interlaboratory variations of fluoroquinolone susceptibility testing. An international study to validate the quality of microbiology results reported during the fleroxacin clinical trials. Diagn. Microbiol. Infect. Dis., 17: 225, 1993.
17. Gasser, T. C., Graverson, P. H. and Madson, P. O.: Treatment of complicated urinary tract infections with ciprofloxacin. Amer. J. Med., suppl. 4A, 82: 278, 1986.
18. Graninger, W., Wenisch, C. and Presterl, E.: Quinolones in the treatment of complicating urinary tract infection. Int. J. Antimicrob. Agents, suppl. 2, 4: S29, 1994.
19. Rubin, R. H., Shapiro, E. D., Andriole, V. T., Davis, R. J. and Stamm, W. E.: Evaluation of new anti-infective drugs for the treatment of urinary tract infections. Infectious Diseases Society of America and Food and Drug Administration. Clin. Infect. Dis., suppl. 15: S216, 1992.
20. Westenfelder, M. and Zeman, W.: A multicenter study of lomefloxacin versus ciprofloxacin in the treatment of complicated urinary tract infections. Int. J. Antimircob. Agents, 2: 29, 1992.
21. Norrby, S. R.: Side-effects of quinolones: comparisons between quinolones and other antibiotics. Eur. J. Clin. Microbiol. Infect. Dis., 10: 378, 1991.
22. Schacht, P., Arcierci, G., Branolte, J., Bruck, H., Chysky, V., Griffith, E., Gruenwaldt, G., Hullmann, R., Konopka, C. A. and O'Brien, B.: Worldwide clinical data on efficacy and safety of ciprofloxacin. Infection, suppl., 16: S29, 1988.
23. Gonzalez, J. P. and Henwood, J. M.: Defloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs, 37: 628, 1989.